Table 1.
Patients’ baseline characteristics of the included patients
| Characteristics | N = 120 |
|---|---|
| Age of diagnosis, year, median (IQR) | 59 (49, 66) |
| Age of diagnosis >60 year, n (%) | 52 (43.3) |
| Male sex, n (%) | 62 (51.7) |
| Symptoms and signs | |
| Asymptomatic, n (%) | 28 (23.3) |
| Fatigue, n (%) | 69 (57.5) |
| Recurrent infections, n (%) | 22 (18.3) |
| Autoimmune phenomenon, n (%) | 48 (40) |
| B symptoms, n (%) | 24 (20) |
| Hepatomegaly, n (%) | 4 (3.3) |
| Splenomegaly, n (%) | 24 (20) |
| Lymphadenopathy, n (%) | 18 (15) |
| ECOG PS >2, n (%) | 13 (10.8) |
| Laboratory tests | |
| LGL, × 109/L, median (IQR) | 2.91 (1.11, 4.42) |
| LGL <1 × 109/L, n (%) | 23 (19.2) |
| ALC, × 109/L, median (IQR) | 3.6 (2.06, 6.52) |
| ALC >4 × 109/L, n (%) | 55 (45.8) |
| ANC, × 109/L, median (IQR) | 1.40 (0.89, 2.46) |
| ANC <1 × 109/L, n (%) | 36 (30) |
| ANC <0.5 × 109/L, n (%) | 14 (11.6) |
| Hemoglobin, g/L, median (IQR) | 84.5 (64, 114.5) |
| Hemoglobin <110 g/L, n (%) | 84 (70) |
| Platelets, × 109/L, median (IQR) | 179.5 (130.75, 232.25) |
| Platelets <100 × 109/L, n (%) | 22 (18.3) |
| LDH, U/L, median (IQR) | 202 (176, 242) |
| LDH > UNL, n (%) | 19 (15.8) |
| Positive STAT3 mutations, n (%) | 14 (17.5) |
| Comorbidity | |
| Pure red-cell anemia, n (%) | 30 (25) |
| Rheumatoid arthritis, n (%) | 6 (5) |
| aCCI score >2, n (%) | 32 (26.7) |
Missing data: STAT3 mutations (n = 40)
IQR: interquartile range; ECOG PS: Eastern Cooperative Oncology Group performance status; LGL: large granular lymphocyte; ALC: absolute lymphocyte count; ANC: absolute neutrophil count; LDH: lactate dehydrogenase; UNL: upper normal limit; aCCI: age-adjusted Charlson Comorbidity Index.